Yang Liu

发表

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

S. Xu, M. Rizk, Pratik Bhagunde, 2019, British journal of clinical pharmacology.

Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects

F. Gheyas, Yang Liu, R. Krishna, 2021, Advances in Therapy.

Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects

F. Gheyas, O. Laterza, J. Wagner, 2018, Journal of clinical pharmacology.

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib

R. Preston, J. Wagner, Yang Liu, 2014, Journal of clinical pharmacology.

Effects of Rifampin, a Potent Inducer of Drug‐Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib

Yang Liu, D. Gutstein, J. Cote, 2013, Journal of clinical pharmacology.

Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

J. Wagner, Yang Liu, R. Krishna, 2012, British Journal of Clinical Pharmacology.

Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.

J. Wagner, Yang Liu, R. Krishna, 2011, Biopharmaceutics & drug disposition.

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

M. Rizk, Pratik Bhagunde, Francheska M. Colón-González, 2020, Clinical pharmacology in drug development.

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

A. Gotto, C. Cannon, P. Barter, 2014, Journal of cardiovascular pharmacology and therapeutics.

A Single‐Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects

D. Tatosian, Yang Liu, M. Murphy, 2012, Clinical pharmacology in drug development.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

D. Rader, S. Previs, B. Hubbard, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin

Yang Liu, K. Yee, Tamara D. Cabalu, 2020, Journal of clinical pharmacology.

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

M. Rizk, Francheska M. Colón-González, Yang Liu, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Biodistribution of Aurantiamide and Aurantiamide Acetate in Rats after Oral Administration of Portulaca oleracea L. Extracts.

Xiao Liang, Hongsheng Liu, Jinhua Zhao, 2016, Journal of agricultural and food chemistry.

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

R. Mogg, Yang Liu, D. Panebianco, 2021, Clinical and translational science.

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

M. Däumer, Saijuan Zhang, J. Hofmann, 2021, Journal of acquired immune deficiency syndromes.

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S]

R. Krauss, C. Pinto, J. Wagner, 2012, Journal of Lipid Research.

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S]

Michael E. Lassman, D. Rader, H. Ginsberg, 2017, Journal of Lipid Research.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2015, The Journal of clinical investigation.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

R. Krauss, C. Pinto, Yang Liu, 2015, Journal of clinical lipidology.

Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans

S. Fukushima, T. Hayakawa, Guohua Ding, 2007, The Journal of pharmacy and pharmacology.

Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism

Di Wu, Yang Liu, Liran Cui, 2020, Pharmaceutical biology.

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers

J. Wagner, Yang Liu, A. Johnson‐Levonas, 2014, Journal of clinical pharmacology.

Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

G. Bormans, K. Van Laere, R. Hargreaves, 2012, Clinical pharmacology and therapeutics.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, Arteriosclerosis, thrombosis, and vascular biology.